Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive phenotype and the scarcity of druggable targets. Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a critical driver of TNBC progression, yet its has precluded the development of conventional occupancy-driven inhibitors. In this study, we employed an event-driven proteolysis-targeting chimera (PROTAC) strategy to target this “undruggable” LRG1 for degradation. Leveraging our previously developed ETTAC-2─a peptide-based PROTAC with established efficacy in ocular neovascularization and renal fibrosis models─we demonstrate that this degrader induces effective LRG1 degradation via the ubiquitin-proteasome system in a dose- and time-dependent manner in 4T1 TNBC cells. Mechanistically, ETTAC-2-mediated degradation of LRG1 suppressed the p-AKT and HIF-1α signaling axes, impairing cell proliferation in vitro and orchestrating a robust antitumor response in vivo. Systemic administration of ETTAC-2 significantly attenuated mammary tumor growth and impeded the aggressive phenotype by reversing the epithelial-mesenchymal transition (EMT) program through sustained inhibition of HIF-1α signaling. By effectively reversing EMT markers and curtailing the malignant progression of TNBC without observable systemic toxicity, our findings validate LRG1 as a viable therapeutic target and establish ETTAC-2 as a pioneering lead compound that bypasses structural limitations to treat recalcitrant breast cancers.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: